Circle Internet Group Inc. Class A Common Stock vs Novavax Inc — how do they compare? Circle Internet Group Inc. Class A Common Stock trades at $82.27 (market cap $20.52B), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Circle Internet Group Inc. Class A Common Stock is far larger — about 11.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Circle Internet Group Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Circle Internet Group Inc. Class A Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| CRCL | NVAX | |
|---|---|---|
Market Cap | $20.52B | $1.82B |
Volume | 9,813,610 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $150.48 | $12.56 |
52-Week Low | $50.23 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $19.03B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Circle Internet Group provides internet financial infrastructure centered on its stablecoin network. Its business includes stablecoins, blockchain infrastructure for developers, digital-asset services, and payment applications.
Read more on CRCL →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →